Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Debt / NOTE 1.250% 5/1
-
Number of holders
-
66
-
Total 13F principal, excl. options
-
537,501,514
-
Principal change
-
+86,857,634
-
Total reported value, excl. options
-
$507,973,851
-
Value change
-
+$81,756,015
-
Number of buys
-
26
-
Number of sells
-
-29
-
Price
-
$0.9413
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2025
77 filings reported holding 09061GAK7 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2025.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 has 66 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $537,501,514 of principal
.
Largest 10 bondholders include TENOR CAPITAL MANAGEMENT Co., L.P. ($77,575,000 of principal), Voya Investment Management LLC ($69,530,000 of principal), AQR Arbitrage LLC ($54,125,000 of principal), Wellesley Asset Management ($50,624,000 of principal), MACKAY SHIELDS LLC ($44,297,000 of principal), BlackRock, Inc. ($37,858,000 of principal), BNP PARIBAS FINANCIAL MARKETS ($22,717,000 of principal), READYSTATE ASSET MANAGEMENT LP ($20,000,000 of principal), VICTORY CAPITAL MANAGEMENT INC ($19,254,000 of principal), and LAZARD ASSET MANAGEMENT LLC ($16,182,000 of principal).
This table shows the top 66 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.